Skip to main content

Clinical Trials Using Mosunetuzumab

Review the clinical trials studying mosunetuzumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Status: Active
Location: 228 locations
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Status: Active
Location: 85 locations
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Status: Active
Location: 33 locations
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Status: Active
Location: 14 locations
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Status: Active
Location: 12 locations
Mosunetuzumab Alone or with Zanubrutinib for the Treatment of Newly Diagnosed Follicular Lymphoma
Status: Active
Location: 9 locations
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 6 locations
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: 7 locations
Mosunetuzumab for the Treatment of Patients with Newly Diagnosed Extranodal Marginal Zone Lymphoma
Status: Active
Location: 4 locations
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Status: Active
Location: 4 locations
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: Active
Location: 4 locations
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: 2 locations
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Status: Active
Location: 2 locations
Mosunetuzumab or Glofitamab for the Treatment of Relapsed or Refractory Diffuse Large B-cell or Transformed Follicular Lymphoma After Receiving CAR T-cell Therapy
Status: Active
Location: 2 locations
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
Status: Active
Location: 3 locations
Low Dose Mosunetuzumab for the Treatment of Patients with Indolent B-Cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide for the Treatment of Relapsed B-Cell Non-Hodgkin’s Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mosunetuzumab and Zanubrutinib for the Treatment of Patients with Relapsed or Refractory Marginal Zone Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Genetically Engineered Cells (Anti-CD19 CAR-T Cell Therapy) and Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Refractory/Relapsed Aggressive Non-Hodgkin Lymphoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Mosunetuzumab with Chemotherapy for the Treatment of Patients with Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Mosunetuzumab after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Aggressive B Cell Lymphoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Mosunetuzumab in Combination with Platinum-Based Salvage Chemotherapy for the Treatment of Relapsed/Refractory Aggressive B Cell Lymphoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for Follicular and Marginal Zone Lymphoma
Status: Active
Location: 14 locations